Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
The authors compare multiple senolytic strategies including FOXO4-DRI, dasatinib plus quercetin, navitoclax, and fisetin, evaluating mechanisms of action, selectivity profiles, and safety considerations for each approach
Buyer assumes all responsibility for compliance.
E., Puri, V., Lee, K
This product is not covered by insurance
Its use is only permitted within formally approved clinical trials
US$ 20.07
US$ 26.69
US$ 27.30
US$ 25.14
